| 2026-08-14 | Press release | HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results |
| 2026-07-29 | Press release | HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering |
| 2026-07-23 | Press release | HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-Generation T-Cell Engager Program On Track To In |
| 2026-06-30 | Press release | HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter |
| 2026-06-26 | Press release | HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026 |
| 2026-06-16 | Press release | HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 B |
| 2026-05-27 | Press release | HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen |
| 2026-05-21 | Press release | HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq |
| 2026-05-14 | Press release | HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results |
| 2026-05-14 | Press release | HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling Studies |
| Press release | HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum |
| Press release | HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue |
| Press release | HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results |
| Press release | HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic |
| Press release | HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Pro |
| Press release | HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter |
| Press release | HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules |
| Press release | HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune |
| Press release | HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules |
| Press release | HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease |
| Press release | HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results |
| Press release | HCW Biologics Shares the Latest Data for its Second-Generation Immune Checkpoint Inhibitor Presented at the 40th Annual |
| Press release | HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer |
| Press release | HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment |
| Press release | HCW Biologics to Participate in the 2025 Maxim Growth Summit |
| Press release | HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cel |
| Press release | HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing |
| Press release | HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise I |
| Press release | HCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager |
| Press release | HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a |
| Press release | HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results |
| Press release | HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific |
| Press release | HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements |
| Press release | HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech |
| Press release | HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results |
| Press release | HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules |
| Press release | HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercializat |
| Press release | HCW Biologics Announces 1-for-40 Reverse Stock Split |
| Press release | HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results |
| Press release | HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements |